Minireviews
©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 787-799
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.787
Table 1 Real-world studies of gemcitabine/nab-paclitaxel in the first-line setting[
19-23]
| Ref. | Location | Study design | Stage M1 | n | Regimen | mOS in mo | Subgroup analysis | mPFS in mo | Remarks |
| Prager et al[19], 2021 | Austria | Prospective cohort | 100% | 317 | GnP | 10.6/10.2 | Age < 70/> 70 | 5.6/5.5 | No difference in frequent toxicities |
| Blomstrand et al[20,21], 2019/2020 | Sweden | Retrospective cohort | 71% | 75 | GnP | 10.9 | Alb <3 7, age < 65 with shorter survival | 5.2 | Less hematotoxicity than MPACT |
| Ostwal et al[22], 2018 | India | Retrospective cohort | 83% | 78 | GnP | 11.6 | | 5.6 | Grade III-IV toxicity 35% |
| Quinton et al[23], 2018 | United Kingdom | Retrospective cohort | 100% | 74 | | 8.4 | | - | Hematotoxicity similar to MPACT |
Table 2 Real-world studies of Folfirinox in the first-line setting[
24]
| Ref. | Location | Study design | n | M1 | Regimen | mOS in mo | mPFS in mo | Remarks |
| Cavanna et al[24], 2019 | Italy | Retrospective cohort | 50 | 74% | FFX/mFFX | 10.1 | 5.6 | mFFX sign less toxicity |
Table 3 Real-world studies comparing Folfirinox and Gemcitabine/Nab-paclitaxel in the first-line setting[
25-32]
| Ref. | Location | Study design | n | M1 | Regimen | mOS in mo, P value | Prognostic factors | mPFS in mo, P value | Remarks |
| Franco et al[25], 2020 | Spain | Retrospective cohort | 119 | 50% | FFX 59; GnP 60 | FFX 12.7; GnP 10.2; P = 0.912 | Ca19-9, NLR | - | Toxicity data not reported |
| Wang et al[26], 2019 | Canada | Retrospective cohort | 225 | 58% | FFX 92; GnP 87; Gem 46 | FFX 14.1; GnP 10.5; Gem 4.2 | - | FFX 8.4; GnP 8.5; Gem 3.7 | Sign more hematotoxicity in FFX |
| Pusceddu et al[27], 2019 | - | Review | 3813 | NA | FFX 1690; GnP 2123 | 1.15 longer for FFX. P = 0.03 | - | - | GnP more neurotoxicity and anemia. FFX more neutropenia |
| Chiorean et al[28], 2019 | - | Review | > 6915 | NA | FFX > 3556; GnP > 3359 | FFX 15.9; GnP 14.4 | - | FFX 11.7; GnP 8.5 | FFX more neutropenia, GnP more neuropathy |
| Papneja et al[29], 2019 | Canada | Retrospective cohort | 119 | 77% | FFX 86; GnP 33 | FFX 9.0; GnP 9.0 | S-Alb, male sex, 2nd line therapy | FFX 6.0; GnP 4.0 | Grade 1-2 thromboembolism, mucositis and neuropathy sign more in FFX. Among grade 3-4 toxicity only fatigue sign more in GnP group |
| Kordes et al[32], 2019 | Sweden | Retrospective cohort | 595 | - | FFX 31; GnP 66; Gem 185 | FFX 9.9; GnP 9.8; Gem 6.6 | - | - | No sign differences in toxicity comparing FFX vs GnP |
| Cartwright et al[30], 2018 | United States | Retrospective cohort | 486 | 100% | FFX 159; GnP 255; Gem 72 | FFX 11.4; GnP 9.8; Gem 4.4 | - | - | No sign differences in toxicity comparing FFX vs GnP |
| Kim et al[31], 2018 | United States | Retrospective cohort | 654 | 100% | FFX 317; GnP 337 | FFX 13.8; GnP 12.1; P = 0.96 | Age | - | Less toxicity in GnP group |
Table 4 Real-world studies of second-line therapy following failure of Folfirinox[
36-44]
| Ref. | n | M1 | 2L regimen | mPFS in mo | mOS in mo | Remarks | AE |
| Portal et al[36], 2015 | 57 | 100% | GnP | 5.1 | 8.8 | Prospective cohort | 38% grade 3-4 toxicity |
| Mita et al[37], 2019 | 30 | 80% | GnP | 3.8 | 7.6 | Phase II | 70% grade 3-4 toxicity |
| Tsang et al[38], 2019 | 159 | 67% | GnP 78; Gem 81 | - | 5.8; 4.6 | Population-based, three Canadian provinces | - |
| Zhang et al[39], 2018 | 60 | 73%; 75%; 73% | GnP 30; Gem 8; BSC 22 | 3.6; 2.5 | 5.7; 3.8 | Single center | More grade 3-4 fatigue in Gem |
| Nguyen et al[40], 2017 | 30 | 77% | GnP | 3.7 | 12.4 | Single center | Grade 3-4 thrombocytopenia (33%), anemia (23%), nausea (17%) |
| Bertocchi et al[41], 2015 | 23 | 100% | GnP | 3.0 | 5.0 | Single center | - |
| Zhang et al[42], 2015 | 28 | 82% | GnP | 3.0 | 5.7 | Single center | Grade 3-4, anemia (25%), thrombocytopenia (25%), neutropenia (18%) |
| Caparello et al[44], 2016 | 71 | - | GnP | 2.5 | 6.2 | Single center | - |
| Rissy et al[43], 2017 | 12 | 100% | GnP | 4.9 | - | Single-center | No grade 3-4 toxicity reported |
Table 5 Real-world studies of second-line treatment with Folfirinox following failure of gemcitabine/nab-paclitaxel or single-agent gemcitabine[
46-51]
| Ref. | n | M1 | 1L regimen | 2L regimen | mPFS in mo | mOS in mo | Remarks |
| Sawada et al[46], 2020 | 104 | 100% | GnP | Modified; FFX | 3.9 | 7.0 | Bolus 5-FU omitted. 55% grade 3-4 toxicity |
| Matsumoto et al[47], 2020 | 23 | 83% | GnP | FFX 12; mFFX 11 | 5.3; 4.3 | 6.9; 12.8 | No sign difference in toxicity between FFX/mFFX |
| Assaf et al[50], 2011 | 27 | 100% | Gem | FFX | 3.0 | 8.5 | 56% grade 3-4 neutropenia |
| Kobayashi et al[48], 2017 | 18 | 100% | Gem | FFX | 2.8 | 9.8 | Phase I/II. 83% grade 3-4 toxicity |
| Kim et al[51], 2018 | 39 | 82% | Gem | Attenuated; FFX | 3.8 | 8.5 | Oxaliplatin: 65 mg/m2. 41% grade 3-4 neutropenia |
| Chung et al[49], 2018 | 48 | 79% | Gem | Reduced irinotecan and oxaliplatin; FFX | 5.8 | 9.0 | Phase IIIrinotecan: 120 mg/m2; Oxaliplatin: 60 mg/m2; 65% grade 3-4 neutropenia |